In Silico Investigation of the New UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 Variants with a Focus at the ACE2–Spike RBD Interface
SARS-CoV-2 exploits angiotensin-converting enzyme 2 (ACE2) as a receptor to invade cells. It has been reported that the UK and South African strains may have higher transmission capabilities, eventually in part due to amino acid substitutions on the SARS-CoV-2 Spike protein. The pathogenicity seems...
Main Authors: | Bruno O. Villoutreix, Vincent Calvez, Anne-Geneviève Marcelin, Abdel-Majid Khatib |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-02-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/4/1695 |
Similar Items
-
501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro
by: Haolin Liu, et al.
Published: (2021-01-01) -
Possible Role of Accessory Proteins in the Viral Replication for the 20I/501Y.V1 (B.1.1.7) SARS CoV-2 Variant
by: Dimpal A. Nyayanit, et al.
Published: (2021-12-01) -
A Collection of Designed Peptides to Target SARS-CoV-2 Spike RBD—ACE2 Interaction
by: Narcis Fernandez-Fuentes, et al.
Published: (2021-10-01) -
Biochemical Characterization of SARS-CoV-2 Spike RBD Mutations and Their Impact on ACE2 Receptor Binding
by: Abdullah Hoter, et al.
Published: (2022-05-01) -
Transcriptional regulation of SARS-CoV-2 receptor ACE2 by SP1
by: Hui Han, et al.
Published: (2024-02-01)